Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 392 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed654    
    Printed33    
    Emailed0    
    PDF Downloaded69    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 2000  |  Volume : 42  |  Issue : 3  |  Page : 302-307

Of the Efficacy and Adverse Effect Profile of Sustained-Release Alprazolam


1 Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
2 Research Assistant, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
3 Additional Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
4 Additional Professor, National Institute of Mental Health and Neurosciences, Bangalore-560 029, India
5 Chief Consultant, Department of Psychiatry, St. Martha's Hospital, Bangalore-560 009, India

Correspondence Address:
Chittaranjan Andrade
Additional Professor & Head, Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore-560 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21407961

Rights and PermissionsRights and Permissions

In a double-blind, prospective study, 40 patients diagnosed with DSM-IV generalized anxiety disorder and stabilized on alprazolam therapy were randomized to receive the same dose of either conventional or sustained-released alprazolam for two weeks, followed by the other formulation of alprazolam in an identical dose for a further two weeks. Conventional alprazolam was administered thrice daily while the sustained-release formulation was administered once-daily, in the morning. Thirty four patients completed the study. Recruitment into the study was associated with a significant decrease in all measures of illness severity; however, no efficacy differences between the two forms of alprazolam were observed. Adverse effects, specifically insomnia, were reported more with the sustained-release formulation. It is concluded that once-daily sustained-release alprazolam is as effective as the conventional form of the drug, and may be preferable because of a wide range of advantages; in this study, the higher incidence of adverse effects with the sustained-release drug was probably an artefact of the experimental design, which fostered a (nighttime) state of partial drug withdrawal.



[PDF]*

        

Print this article         Email this article